Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to see whether a new self-sampling device, the Delphi Screener (Delphi Devices, Scherpenzeel, Netherlands), can be used for cervical cancer screening. The results using the new device will be compared to results using the current gold standard. The gold standard is clinician-collected endo-cervical and ecto-cervical specimens (often referred to as a 'Pap smear'). Additionally, women will be asked about the acceptability of using the device and how easy it is to understand the user instructions.

The Delphi Screener is a sterile, plastic, syringe-like device containing buffered saline which allows a woman to collect her own vaginal lavage (to 'self-squirt'). The hypothesis is that the device may work well for cervical cytology and will be acceptable to the women in the study.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening


Related Conditions & MeSH terms


NCT number NCT00702208
Study type Interventional
Source Columbia University
Contact
Status Completed
Phase Phase 2
Start date September 2008
Completion date January 2010

See also
  Status Clinical Trial Phase
Completed NCT02253719 - Cervical Cancer Screening in HIV Positive and Negative Women in Cambodia N/A
Completed NCT05211271 - Evaluating Thermal Ablation in the Treatment of Cervical Neoplasia N/A
Not yet recruiting NCT02908607 - Thermal Imaging for Evaluation of the Cervix Phase 1/Phase 2
Withdrawn NCT00503919 - Measurement of Digital Colposcopy for Fluorescence Spectroscopy of TNC Using a Second Device Phase 1
Terminated NCT00342173 - Costa Rican Natural History Study of HPV and Cervical Neoplasia
Completed NCT00435214 - Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer
Completed NCT01086709 - Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
Completed NCT00766701 - Spectroscopic Evaluation of Cervical Neoplasia N/A
Completed NCT00456807 - Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Phase 3